Join us for a quick overview of Elanco Animal Health, a Pharmaceutical company whose shares moved -0.6% today. Here are some facts about the stock that should help you see the bigger picture:
-
Elanco Animal Health has moved -12.0% over the last year, and the S&P 500 logged a change of 18.0%
-
ELAN has an average analyst rating of hold and is -22.99% away from its mean target price of $13.81 per share
-
Its trailing earnings per share (EPS) is $-0.23
-
Elanco Animal Health has a trailing 12 month Price to Earnings (P/E) ratio of -46.2 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $0.91 and its forward P/E ratio is 11.7
-
The company has a Price to Book (P/B) ratio of 0.71 in contrast to the S&P 500's average ratio of 2.95
-
Elanco Animal Health is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana.
